These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8311654)

  • 1. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas.
    Zhang SY; Ruggeri B; Agarwal P; Sorling AF; Obara T; Ura H; Namiki M; Klein-Szanto AJ
    Arch Pathol Lab Med; 1994 Feb; 118(2):150-4. PubMed ID: 8311654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 protein expression in intraductal papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancy.
    Kawahira H; Kobayashi S; Kaneko K; Asano T; Ochiai T
    Hepatogastroenterology; 2000; 47(34):973-7. PubMed ID: 11020860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours.
    Uemura K; Hiyama E; Murakami Y; Kanehiro T; Ohge H; Sueda T; Yokoyama T
    Oncol Rep; 2003; 10(2):277-83. PubMed ID: 12579258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ki-ras and p53 gene mutations in pancreatic ductal carcinoma: a relationship with tumor phenotype and survival.
    Sessa F; Bonato M; Bisoni D; Ranzani GN; Capella C
    Eur J Histochem; 1998; 42 Spec No():67-76. PubMed ID: 10076772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 protein expression as prognostic factor in human pancreatic cancer.
    Sato Y; Nio Y; Song MM; Sumi S; Hirahara N; Minari Y; Tamura K
    Anticancer Res; 1997; 17(4A):2779-88. PubMed ID: 9252715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes.
    Ruggeri B; Zhang SY; Caamano J; DiRado M; Flynn SD; Klein-Szanto AJ
    Oncogene; 1992 Aug; 7(8):1503-11. PubMed ID: 1630814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Morphologic, morphometric and immunohistochemical studies on pancreatic intraductal hyperplasia and infiltrating carcinoma].
    Tomaszewska R
    Folia Med Cracov; 1999; 40(1-2):101-41. PubMed ID: 10909469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.
    Yamasawa K; Nio Y; Dong M; Yamaguchi K; Itakura M
    Clin Cancer Res; 2002 Aug; 8(8):2563-9. PubMed ID: 12171884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
    Ueda M; Miura Y; Kunihiro O; Ishikawa T; Ichikawa Y; Endo I; Sekido H; Togo S; Shimada H
    Hepatogastroenterology; 2005; 52(62):398-403. PubMed ID: 15816444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of protein expression and clinical features.
    Nishikawa N; Kimura Y; Okita K; Zembutsu H; Furuhata T; Katsuramaki T; Kimura S; Asanuma H; Hirata K
    J Hepatobiliary Pancreat Surg; 2006; 13(4):327-35. PubMed ID: 16858545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical analysis of molecular biological factors in intraductal papillary-mucinous tumors and mucinous cystic tumors of the pancreas.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Tanaka M; Manabe T
    Scand J Gastroenterol; 2004 Nov; 39(11):1159-65. PubMed ID: 15545177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
    Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y
    Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infrequent expression of p21 is related to altered p53 protein in pancreatic carcinoma.
    Hu YX; Watanabe H; Ohtsubo K; Yamaguchi Y; Ha A; Motoo Y; Okai T; Sawabu N
    Clin Cancer Res; 1998 May; 4(5):1147-52. PubMed ID: 9607571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expressions of p53 and Gadd45a proteins in human pancreatic cancer and their clinicopathological significance].
    Dong M; Zhou JP; Kong FM; Guo KJ; Tian YL; Dong YT
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Oct; 27(5):628-32. PubMed ID: 16274047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunohistochemical analysis of p53 and c-erbB-2 in breast cancer].
    Castiglioni T; Elsner B; Curutchet HP; Montesinos M; Debonis D
    Medicina (B Aires); 1995; 55(5 Pt 1):415-20. PubMed ID: 8728771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines.
    Huang L; Lang D; Geradts J; Obara T; Klein-Szanto AJ; Lynch HT; Ruggeri BA
    Mol Carcinog; 1996 Feb; 15(2):85-95. PubMed ID: 8599583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53 protein expression in pancreatic tumors and its relationship to clinicopathological factors and prognosis.
    Aizawa S; Sasaki M; Wada R; Koyama M; Yagihashi S
    J Surg Oncol; 1996 Aug; 62(4):279-83. PubMed ID: 8691842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
    Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
    Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
    Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
    Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas.
    Sasaki S; Yamamoto H; Kaneto H; Ozeki I; Adachi Y; Takagi H; Matsumoto T; Itoh H; Nagakawa T; Miyakawa H; Muraoka S; Fujinaga A; Suga T; Satoh M; Itoh F; Endo T; Imai K
    Oncol Rep; 2003; 10(1):21-5. PubMed ID: 12469138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.